BR112022025191A2 - Compostos de imidazopiridazina com atividade de inibidores de alk2 - Google Patents

Compostos de imidazopiridazina com atividade de inibidores de alk2

Info

Publication number
BR112022025191A2
BR112022025191A2 BR112022025191A BR112022025191A BR112022025191A2 BR 112022025191 A2 BR112022025191 A2 BR 112022025191A2 BR 112022025191 A BR112022025191 A BR 112022025191A BR 112022025191 A BR112022025191 A BR 112022025191A BR 112022025191 A2 BR112022025191 A2 BR 112022025191A2
Authority
BR
Brazil
Prior art keywords
compounds
alk2
inhibitory activity
imidazopyridazine compounds
imidazopyridazine
Prior art date
Application number
BR112022025191A
Other languages
English (en)
Inventor
Pan Jun
Bai Yu
Wu Liangxing
Yao Wenqing
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of BR112022025191A2 publication Critical patent/BR112022025191A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A presente invenção refere-se a compostos de Fórmula (I), métodos de uso dos compostos para inibir a atividade de ALK2 e composições farmacêuticas que compreendem tais compostos. Os compostos são úteis no tratamento, na prevenção ou na melhoria de doenças ou distúrbios associados à atividade de ALK2, como câncer. (I)
BR112022025191A 2020-06-12 2021-06-10 Compostos de imidazopiridazina com atividade de inibidores de alk2 BR112022025191A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12
PCT/US2021/036839 WO2021252781A1 (en) 2020-06-12 2021-06-10 Imidazopyridazine compounds with activity as alk2 inhibitors

Publications (1)

Publication Number Publication Date
BR112022025191A2 true BR112022025191A2 (pt) 2023-03-07

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025191A BR112022025191A2 (pt) 2020-06-12 2021-06-10 Compostos de imidazopiridazina com atividade de inibidores de alk2

Country Status (17)

Country Link
US (2) US11840546B2 (pt)
EP (1) EP4165051A1 (pt)
JP (1) JP2023530088A (pt)
KR (1) KR20230025434A (pt)
CN (1) CN115956081A (pt)
AR (1) AR122587A1 (pt)
AU (1) AU2021288107A1 (pt)
BR (1) BR112022025191A2 (pt)
CA (1) CA3184811A1 (pt)
CL (1) CL2022003453A1 (pt)
CO (1) CO2022017969A2 (pt)
EC (1) ECSP22093652A (pt)
IL (1) IL298248A (pt)
MX (1) MX2022015493A (pt)
PE (1) PE20230491A1 (pt)
TW (1) TW202214660A (pt)
WO (1) WO2021252781A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898627A1 (en) 2018-12-20 2021-10-27 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000051A (es) 2000-06-28 2003-08-19 Smithkline Beecham Plc Procedimiento de molido en humedo.
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
US8367662B2 (en) 2007-10-17 2013-02-05 Novartis Ag Organic compounds
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3377488T3 (pl) 2015-11-19 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
ES2844374T3 (es) 2015-12-22 2021-07-22 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
IL263825B (en) 2016-06-20 2022-08-01 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3512834A4 (en) 2016-09-14 2020-05-06 Vanderbilt University INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
CA3036101A1 (en) 2016-09-15 2018-03-22 Armstrong World Industries, Inc. Ceiling system with air movement
ES2918974T3 (es) 2016-12-22 2022-07-21 Incyte Corp Compuestos heteroaromaticos biciclicos como inmunomoduladores
CA3047986A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018136634A1 (en) * 2017-01-18 2018-07-26 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
EP3898627A1 (en) * 2018-12-20 2021-10-27 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
US20240083918A1 (en) 2024-03-14
CN115956081A (zh) 2023-04-11
US20210388003A1 (en) 2021-12-16
WO2021252781A1 (en) 2021-12-16
JP2023530088A (ja) 2023-07-13
ECSP22093652A (es) 2023-02-28
PE20230491A1 (es) 2023-03-23
CL2022003453A1 (es) 2023-05-26
MX2022015493A (es) 2023-03-21
CA3184811A1 (en) 2021-12-16
KR20230025434A (ko) 2023-02-21
AR122587A1 (es) 2022-09-21
IL298248A (en) 2023-01-01
TW202214660A (zh) 2022-04-16
CO2022017969A2 (es) 2023-02-27
EP4165051A1 (en) 2023-04-19
US11840546B2 (en) 2023-12-12
AU2021288107A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
ECSP24009853A (es) Compuestos tricíclicos como inhibidores de kras
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112022019492A2 (pt) Inibidores de rip1k
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022001628A2 (pt) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022020798A2 (pt) Compostos tricíclicos como inibidores de nlrp3
BR112022001390A2 (pt) Inibidores de enzima